Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone Approved to Start China Trials of PD-L1 Candidate

publication date: Jul 17, 2017
CStone Pharma of Suzhou announced its PD-L1 monoclonal antibody, CS1001, was approved to begin clinical trials in China by the CFDA. One year ago, CStone raised $150 million in an A round from three China investors -- Oriza, Boyu and WuXi Healthcare. CStone said CS1001, which was approved after an eight-month review, is China's first fully human, full-length PD-L1 mAb to begin trials, although several PD-1 candidates have already started the clinical process. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital